UPDATE: Aegis Capital Initiates Buy On Sorrento Therapeutics On RTX-100

In a report published Tuesday, Aegis Captial analyst Raghuram Selvaraju initiated a Buy rating on Sorrento Therapeutics SRNE and a price target of $40.00. In the report, Aegis Capital says "We are initiating coverage of Sorrento Therapeutics, Inc., with a Buy rating and an 18-month price target of $40.00 per share. In our view, Sorrento is a unique combination - a firm with a risk-mitigated lead asset that could have a rapid path to commercialization in the U.S. via the 505(b)(2) pathway; a novel pain drug, RTX-100, with applicability in both humans and companion animals; and an industry-leading antibody platform." Sorrento Therapeutics closed on Tuesday at $8.50.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorInitiationAnalyst RatingsAegis CapitalRaghuram Selvaraju
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!